Get the Stockscreener App
1,051.24
0.82%
8.55
After Hours:
1054.00
2.76
+0.26%
Regeneron Pharmaceuticals Inc stock is traded at $1,051.24, with a volume of 562.51K.
It is up +0.82% in the last 24 hours and down -11.26% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
See More
Previous Close:
$1,042.69
Open:
$1040.73
24h Volume:
562.51K
Relative Volume:
1.19
Market Cap:
$115.56B
Revenue:
$13.49B
Net Income/Loss:
$4.32B
P/E Ratio:
29.98
EPS:
35.06
Net Cash Flow:
$3.18B
1W Performance:
-3.73%
1M Performance:
-11.26%
6M Performance:
+9.22%
1Y Performance:
+27.74%
1-Day Range:
$1,039.64
$1,058.27
1-Week Range:
$1,008.41
$1,080.00
52-Week Range:
$769.19
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
BMO maintains Outperform rating on Regeneron shares - Investing.com India
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD - Zacks Investment Research
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Simply Wall St
Regeneron's SWOT analysis: biotech giant's stock faces opportunities and challenges - Investing.com
Regeneron, Sanofi’s Dupixent approved to treat COPD in US, China - World Pharmaceutical Frontiers
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio? - Benzinga
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales - Seeking Alpha
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD - MedCity News
Granite FO LLC Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Stock: Long-Term Defensive Investment (NASDAQ:REGN) - Seeking Alpha
Regeneron buys Quad’s 1.1-million-square-foot plant in Saratoga Springs - Times Union
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD - Yahoo Finance
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’ - Insider Monkey
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’ - Yahoo Finance
Susquehanna Fundamental Investments LLC Acquires 22,006 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
(REGN) Investment Report - Stock Traders Daily
Health Care Up on Session, Down on Week, Amid Regulatory Risk -- Health Care Roundup - Marketscreener.com
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD - Investopedia
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling - Bloomberg
FDA greenlights Regeneron’s Dupixent for the treatment of COPD - Yahoo Finance
FDA greenlights Regeneron’s Dupixent for the treatment of COPD - Pharmaceutical Technology
Regeneron, Sanofi win FDA nod for Dupixent in COPD (NASDAQ:REGN) - Seeking Alpha
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval - Pharmaceutical Technology
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease - Benzinga
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung' - Reuters
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback - Bloomberg
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD - The Wall Street Journal
Regeneron buys former Saratoga Springs Quad Graphics facility - The Daily Gazette
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval - FiercePharma
FDA, after delay, clears Regeneron and Sanofi drug for COPD - BioPharma Dive
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD - GlobeNewswire
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent - Investor's Business Daily
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD - StockTitan
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with - The Bakersfield Californian
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD - GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewswire Inc.
FDA, after delay, clears Regeneron and Sanofi drug for COPD - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Public Sector Pension Investment Board - MarketBeat
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion - MSN
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales - MSN
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024 - The Manila Times
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024 - StockTitan
DE Burlo Group Inc. Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar (update) - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics - Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Reduced by DRW Securities LLC - Defense World
Sei Investments Co. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market - Benzinga
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Sep 03 '24 |
Sale |
1,178.73 |
1,000 |
1,178,730 |
12,931 |
| RYAN ARTHUR F | Director |
Sep 03 '24 |
Sale |
1,178.68 |
100 |
117,868 |
17,682 |
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):